Core Viewpoint - Profusa Inc. experienced a significant increase in stock price following the announcement of debt restructuring and measures to reduce potential shareholder dilution, leading to speculative buying in the digital health sector [1]. Debt Restructuring - The primary catalyst for the stock rally was Profusa's decision to restructure its senior secured convertible notes, raising the conversion floor price from $0.10 to $0.35 to stabilize its balance sheet [2]. - By increasing the conversion floor, the company aims to limit new equity issuance at low prices, thereby protecting shareholders from substantial dilution, which is viewed as a positive signal for investors [3]. - Profusa also removed mandatory cash and equity amortization payments that were set to begin in early 2026, providing essential relief for its cash flow [3]. Market Context and Risks - Despite the recent surge, Profusa remains a high-risk micro-cap stock, with its price still significantly lower than its 52-week high of $2.40, as reported by Benzinga Pro [4]. - The stock was noted to be up 73% at $0.11 as it approached the closing bell on Tuesday, indicating a volatile trading environment [4].

Core Viewpoint - Vireo Growth Inc. is pursuing its M&A strategy by acquiring approximately 86% of the outstanding senior secured convertible notes of Medicine Man Technologies Inc. for about $62 million, payable in subordinate voting shares at a price of $0.54 per share [1][2]. Group 1: Transaction Details - The acquisition is expected to close later this month, pending customary conditions and necessary approvals [2]. - The total consideration for the Notes is approximately $62 million, which will be paid in subordinate voting shares [1]. Group 2: Company Background - Vireo Growth Inc. was founded in 2014 as a pioneering medical cannabis company, focusing on a disciplined and execution-oriented platform in the industry [3]. - The company aims to leverage its national portfolio while maintaining a strong local market focus and is committed to deploying capital and talent effectively [3].

Core Viewpoint - 180 Life Sciences Corp. (d/b/a ETHZilla) is focusing on increasing its Ethereum (ETH) holdings through a recent $156 million convertible notes offering, which is part of its broader ETH treasury strategy [1][2][6] Group 1: Financing and Strategy - The company has closed a $425 million private placement and subsequently sold approximately $156 million in senior secured convertible notes due 2028 [1][2] - Proceeds from the convertible notes will primarily be used to purchase more ETH and support the company's ETH treasury strategy [2][3] - The convertible notes will not accrue interest for the first six months and will have a 4% annual interest rate thereafter, maturing three years from the issuance date [2] Group 2: Company Operations and Future Plans - The company aims to rebrand as ETHZilla Corporation and establish itself as a leader in on-chain treasury management among public companies [6] - A significant portion of the company's operations will focus on becoming an ETH accumulation vehicle, designed to provide community access to the Ethereum network [7] - The company plans to implement a differentiated yield generation program in partnership with Electric Capital, aiming to outperform traditional ETH staking [7] Group 3: Legal and Advisory Support - Clear Street LLC acted as the financial advisor and exclusive placement agent for the convertible notes offering, while The Loev Law Firm, PC and Reed Smith LLP provided legal advice to the company [4]